Studies Implemented by Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
| Study Number | Study Title | Study Status | Study Restriction |
|---|---|---|---|
|
(11954) |
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Enrolling |
US & Non-US |
|
(11884) |
A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease |
Enrolling |
Non-US |
|
(10732) |
A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-infected Women in High TB Incidence Settings |
Closed to Follow Up |
Non-US |
|
(10040) |
Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy |
Enrolling |
US & Non-US |
|
(30129) |
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants |
Enrolling |
US & Non-US |
|
(20735) |
Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants |
Pending |
US & Non-US |
|
(12026) |
A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Enrolling |
US & Non-US |
|
(10779) |
HAART Standard Version of the PROMISE Study: Promoting Maternal and Infant Survival Everywhere |
Closed to Follow Up |
US & Non-US |